FrancophonIA/ELRC3.0 huggingface dataset:
English: Increased systolic and arterial blood pressures (up to 29 mm-Hg) were seen in rats and monkeys at systemic exposures 1.4-fold and 4.6-fold greater, respectively, than those achieved with therapeutic doses.
Slovenian: Zvišan sistolični in arterijski krvni tlak (do 29 mm Hg) so opažali pri podganah oz. opicah pri sistemskih izpostavljenostih, ki so bile 1,4-krat oz. 4,6-krat večje od tistih, ki jih dosežemo pri terapevtskih odmerkih.
English: Posaconazole SP belongs to a group of medicines called triazole antifungal agents.
Slovenian: Posaconazole SP sodi v skupino zdravil, ki se imenujejo triazolska protiglivična zdravila (antimikotiki).
English: Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):
Slovenian: Posaconazole SP je indiciran za uporabo pri zdravljenju naslednjih glivičnih okužb pri odraslih (glejte poglavje 5.1):
English: b: In 1899 this was the period from randomization to last dose of study medicinal product plus 7 days; in 316 it was the period from first dose to last dose of study medicinal product plus 7 days.
Slovenian: V študiji 1899 je šlo tu za obdobje od randomizacije do zadnjega odmerka proučevanega zdravila plus 7 dni, v študiji 316 pa je bilo to obdobje od prvega odmerka do zadnjega odmerka proučevanega zdravila plus 7 dni.
English: Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients:
Slovenian: Posaconazole SP je indiciran tudi za profilakso invazivnih glivičnih okužb pri naslednjih bolnikih:
English: Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
Slovenian: Pokazali so, da posakonazol in vitro deluje proti naslednjim mikroorganizmom: Aspergillus sp. (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida sp. (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi in vrste Fusarium, Rhizomucor, Mucor in Rhizopus.
English: However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended.
Slovenian: Ker pa se posakonazol ne izloča v bistveni meri skozi ledvica, ni pričakovati vpliva hude ledvične okvare na farmakokinetiko posakonazola in ni priporočeno nikakršno prilagajanje odmerka.
English: In subjects with severe renal impairment (n=6, Cl cr < 20 ml/min/1.73 m2), the AUC of posaconazole was highly variable [> 96 % CV (coefficient of variance)] compared to other renal groups [< 40 % CV].
Slovenian: Pri preiskovancih s hudo ledvično okvaro (n=6, Cl kr < 20 ml/min/1,73 m2) je bila vrednost AUC posakonazola močno spremenljiva [> 96 % CV (koeficient variance)] v primerjavi z drugimi kategorijami ledvične funkcije [< 40 % CV].
English: • Medicines used to decrease stomach acid such as cimetidine and ranitidine or omeprazole and similar medicines that are called proton pump inhibitors.
Slovenian: • zdravila, ki se uporabljajo za zmanjševanje količine želodčne kisline, kot so cimetidin in ranitidin ali omeprazol ter podobna zdravila, ki jih imenujemo zaviralci protonske črpalke.
English: Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders.
Slovenian: Med 18 bolniki, ki niso prenašali amfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.
English: In the small number of subjects studied who had hepatic impairment, there was an increase in exposure and half-life with a decrease in hepatic function (see sections 4.4 and 5.2).
Slovenian: Pri majhnem številu preiskovancev iz študij, ki so imeli jetrno okvaro, je prišlo do povečanja izpostavljenosti zdravilu in razpolovne dobe zdravila, z zmanjšanjem delovanja jeter (glejte poglavji 4.4 in 5.2).
English: The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels.
Slovenian: Dodatek posakonazola med zdravljenjem z atazanavirjem oziroma z atazanavirjem in ritonavirjem je bil povezan s povečanjem plazemske koncentracije bilirubina.
English: In a study with small number of subjects (n=12) who had hepatic impairment, there was an increase in exposure associated with prolongation of half-life in hepatic impaired patients (26.6, 35.3, and 46.1 hours for the mild, moderate and severe groups, respectively compared to 22.1 hours in subjects with normal hepatic function).
Slovenian: V študiji pri majhnem številu preiskovancev (n=12), ki so imeli jetrno okvaro, so ugotovili povečanje izpostavljenosti zdravilu, povezano s podaljšanjem razpolovne dobe pri bolnikih z jetrno okvaro (26,6 ur za blago, 35,3 ur za zmerno in 46,1 ur za hudo jetrno okvaro, v primerjavi z 22,1 ur pri preiskovancih z normalnim delovanjem jeter).
English: B-1180 Bruxelles Belgium
Slovenian: B-1180 Bruxelles
English: Monitoring of hepatic function: Patients who develop abnormal liver function tests during Posaconazole SP therapy must be routinely monitored for the development of more severe hepatic injury.
Slovenian: Spremljanje delovanja jeter: Bolnike, ki se jim pojavijo nenormalni izvidi preiskav delovanja jeter med zdravljenjem z zdravilom Posaconazole SP, morate rutinsko spremljati, da ugotovite morebiten pojav hujše jetrne poškodbe.
English: After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose).
Slovenian: Po dajanju C-posakonazola so radioaktivnost ugotovili predvsem v blatu (77 % radioaktivno označenega odmerka), glavna komponenta pa je bila matična spojina (66 % radioaktivno označenega odmerka).
English: The effect of posaconazole on CYP3A4 substrates in patients might be somewhat lower than that observed in healthy volunteers, and is expected to be variable between patients due to the variable posaconazole exposure in patients.
Slovenian: Učinek posakonazola na substrate CYP3A4 pa je lahko nekoliko manjši pri bolnikih kot pri zdravih prostovoljcih in pričakujemo lahko, da se bo razlikoval med posameznimi bolniki zaradi različne stopnje izpostavljenosti posakonazolu.
English: During clinical trials, patients who received posaconazole doses up to 1,600 mg/day experienced no different adverse reactions from those reported with patients at the lower doses.
Slovenian: Med kliničnimi preskušanji bolniki, ki so prejeli odmerke posakonazola do 1600 mg/dan, so opazili neželene učinke, ki se niso razlikovali od tistih, prijavljenih pri bolnikih, ki so jemali manjše odmerke.
English: Due to the limited pharmacokinetic data in patients with hepatic impairment, posaconazole should be used with caution in patients with severe hepatic impairment since the prolonged half-life that may occur will lead to increased exposure.
Slovenian: Zaradi omejenih farmakokinetičnih podatkov pri bolnikih z jetrno okvaro morate posakonazol uporabljati previdno pri bolnikih s hudo jetrno okvaro, ker bi podaljšana razpolovna doba, ki lahko nastopi, vodila do povečane izpostavljenosti zdravilu.
English: : 11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole 800 mg/day in divided doses for a median of 124 days and up to 212 days.
Slovenian: : 11 od 24 bolnikov, ki so dokazano ali verjetno imeli fusariozo, so uspešno pozdravili posakonazolom 800 mg/dan v deljenih odmerkih, ki so jih dajali mediano vrednost časa 124 dni ter do 212 dni.
English: Do not use Posaconazole SP after the expiry date which is stated on the label.
Slovenian: Zdravila Posaconazole SP ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki.
English: Posaconazole is excreted into the milk of lactating rats (see section 5.3).
Slovenian: Posakonazol se izloča v mleko pri doječih podganah (glejte poglavje 5.3).
English: • Rifabutin and rifampicin (used to treat certain infections).
Slovenian: • rifabutin in rifampicin (ki ju uporabljamo za zdravljenje določenih okužb).
English: In patients who cannot tolerate a meal or a nutritional supplement, Posaconazole SP should be administered at a dose of 200 mg (5 ml) four times a day.
Slovenian: Pri bolnikih, ki ne morejo jesti hrane ali uživati prehranskih dodatkov, je treba zdravilo Posaconazole SP dajati v odmerku 200 mg (5 ml) štirikrat na dan.
English: Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/ml) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/ml).
Slovenian: Po dajanju 800 mg posakonazola na dan v deljenih odmerkih za zdravljenje invazivnih glivičnih okužb, so bile srednje najmanjše plazemske koncentracije za 12 bolnikov, starih od 8 do 17 let (776 ng/ml), podobne koncentracijam za 194 bolnikov, starih od 18 do 64 let (817 ng/ml).
English: • Midazolam, triazolam, alprazolam and some similar medicines called benzodiazepines (used as sedatives or muscle relaxants)
Slovenian: • midazolam, triazolam, alprazolam in nekatera podobna zdravila, ki jih imenujemo benzodiazepini (in jih uporabljamo kot pomirjevala ali mišične relaksante)
English: Therefore, posaconazole may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing posaconazole treatment.
Slovenian: Zato lahko posakonazol poveča plazemsko koncentracijo digoksina in ob uvedbi ali ukinitvi zdravljenja s posakonazolom je potrebno spremljanje koncentracije digoksina.
English: In twelve-month neurotoxicity studies in dogs and monkeys, no functional effects were observed on the central or peripheral nervous systems at systemic exposures greater than those achieved therapeutically.
Slovenian: V 12-mesečnih študijah nevrotoksičnosti pri psih in opicah niso opažali nobenih funkcionalnih učinkov na osrednje ali periferno živčevje pri sistemskih izpostavljenostih, večjih od tistih, ki jih dosežemo pri terapiji.
English: When initiating treatment with posaconazole in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three quarters of the current dose).
Slovenian: Na začetku zdravljenja s posakonazolom pri bolnikih, ki že prejemajo ciklosporin, je treba zmanjšati odmerek ciklosporina (npr. na približno tri četrtine sedanjega odmerka).
English: Like all medicines, Posaconazole SP can cause side effects, although not everybody gets them.
Slovenian: Kot vsa zdravila ima lahko tudi zdravilo Posaconazole SP neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
English: Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 1.4-fold greater than that achieved therapeutically.
Slovenian: Ehokardiografija ni pokazala nobenih znakov srčne dekompenzacije v študiji farmakološke varnosti večkratnih odmerkov pri podganah pri sistemski izpostavljenosti, ki je bila 1,4-krat večja od tiste, ki jo dosežemo pri terapiji.
English: Uncommon: Rare:
Slovenian: Občasni: Redki:
English: In healthy volunteers under fasting conditions, dividing the total daily dose (800 mg) into 200 mg four times daily compared to 400 mg twice daily, was shown to increase posaconazole exposure by 58 % over 48 hours.
Slovenian: Pri zdravih prostovoljcih na tešče so pokazali, da razdelitev celotnega dnevnega odmerka (800 mg) na 200 mg štirikrat na dan v primerjavi s 400 mg dvakrat na dan poveča izpostavljenost posakonazolu za 58 % v času 48 ur.
English: Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose.
Slovenian: Opravljenih je bilo več študij interakcij posakonazola z drugimi zdravili pri zdravih prostovoljcih, pri katerih je bila izpostavljenost posakonazolu večja kot pri bolnikih, ki so prejemali isti odmerek.
English: Based on pharmacokinetic data in 10 of these paediatric patients, the pharmacokinetic profile appears to be similar to patients ≥ 18 years of age.
Slovenian: Na podlagi farmakokinetičnih podatkov pri 10 od teh pediatričnih bolnikov je videti farmakokinetični profil podoben kot pri bolnikih, starih ≥ 18 let.
English: The effect of coadministration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient, unless posaconazole is administered in a strictly standardised way with food, given the large food effect on posaconazole exposure (see section 5.2).
Slovenian: Učinek sočasne uporabe s posakonazolom na plazemske koncentracije substratov CYP3A4 se lahko spreminja tudi pri posameznem bolniku, razen če prejme posakonazol na strogo standardiziran način s hrano, glede na velik vpliv hrane na izpostavljenost posakonazolu (glejte poglavje 5.2).
English: • halofantrine (used to treat malaria)
Slovenian: • halofantrin (ki ga uporabljamo za zdravljenje malarije)
English: • astemizole (used to treat allergies)
Slovenian: • astemizol (ki ga uporabljamo za zdravljenje alergij)
English: • Diltiazem, verapamil, nifedipine, nisoldipine and some of the other medicines called calcium channel blockers (used to treat high blood pressure)
Slovenian: • diltiazem, verapamil, nifedipin, nisoldipin in nekatera druga zdravila, ki jih imenujemo zaviralci kalcijevih kanalčkov (in jih uporabljamo za zdravljenje zvišanega krvnega tlaka)
English: Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates): Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated.
Slovenian: Terfenadin, astemizol, cisaprid, pimozid, halofantrin in kinidin (substrati CYP3A4): Sočasna uporaba posakonazola in terfenadina, astemizola, cisaprida, pimozida, halofantrina ali kinidina je kontraindicirana.
English: Posaconazole SP must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5).
Slovenian: Zdravila Posaconazole SP ne smete uporabljati skupaj z zdravili, ki so substrati za CYP3A4 in za katere je znano, da podaljšajo interval QTc (glejte poglavji 4.3 in 4.5).
English: In both prophylaxis studies, aspergillosis was the most common breakthrough infection.
Slovenian: V obeh študijah profilaktične uporabe zdravila je bila aspergiloza najpogostejša okužba, ki se je pojavila kljub zdravljenju.
English: If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse events, plasma concentrations of the CYP3A4 substrate and/or adverse events should be closely monitored and the dose adjusted as needed.
Slovenian: Če posakonazol uporabljate sočasno s substrati CYP3A4, ki se uporabljajo peroralno in pri katerih je povečanje plazemske koncentracije lahko povezano z nesprejemljivimi neželenimi pojavi, morate skrbno spremljati plazemske koncentracije substrata CYP3A4 in/ali neželene pojave in po potrebi prilagoditi odmerek zdravila.
English: electrolyte imbalance, anorexia hyperglycaemia
Slovenian: motnje ravnovesja elektrolitov, anoreksija hiperglikemija
English: When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose).
Slovenian: Ob uvedbi zdravljenja s posakonazolom pri bolnikih, ki že prejemajo takrolimus, je potrebno zmanjšati odmerek takrolimusa (npr. na približno tretjino trenutnega odmerka).
English: Posaconazole does not have any major circulating metabolites and its concentrations are unlikely to be altered by inhibitors of CYP450 enzymes.
Slovenian: Posakonazol nima nobenega glavnega presnovka v krvi in malo je verjetno, da bi zaviralci encimov CYP450 vplivali na njegovo koncentracijo.
English: Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for pglycoprotein (P-gp) efflux in vitro.
Slovenian: Posakonazol se presnovi prek UDP glukuronidacije (encimi 2. faze) in je substrat za odtok p-glikoproteina (P-gp) in vitro.
English: Rifabutin: Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively.
Slovenian: Rifabutin: Posakonazol je povečal Cmax rifabutina za 31 %, vrednost AUC za rifabutin pa za 72 %.
English: blurred vision diplopia, scotoma
Slovenian: zamegljen vid diplopija, skotomi
English: hypertension, hypotension pulmonary embolism, deep vein thrombosis
Slovenian: hipertenzija, hipotenzija pljučna embolija, globoka venska tromboza
English: Treatment should be initiated by a physician experienced in the management of fungal infections or in the supportive care in the high risk patients for which posaconazole is indicated as prophylaxis.
Slovenian: Zdravljenje mora uvesti zdravnik, ki je izkušen v zdravljenju glivičnih okužb ali v podporni negi pri bolnikih z velikim tveganjem, pri katerih je posakonazol indiciran za profilakso.
English: Posaconazole SP is a white, cherry flavoured, 105 ml oral suspension packaged in amber glass bottles.
Slovenian: Posaconazole SP je bela 105 ml peroralna suspenzija z okusom češnje, pakirana v stekleničke iz rjavega stekla.
English: Use in hepatic impairment: There are limited pharmacokinetic data in patients with hepatic impairment; therefore, no recommendation for dose adjustment can be made.
Slovenian: Uporaba pri jetrni okvari: Farmakokinetični podatki za bolnike z jetrno okvaro so skopi, zato ni mogoče dati priporočil za prilagajanje odmerka.
English: Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression, and clinical response.
Slovenian: Trajanje terapije je odvisno od stopnje jakosti bolnikove osnovne bolezni, okrevanja po imunosupresiji in bolnikovega kliničnega odziva.
English: Oropharyngeal Candidiasis Loading dose of 200 mg (5 ml) once a day on the first day, then 100 mg (2.5 ml) once a day for 13 days.
Slovenian: Orofaringealna kandidioza Polnilni odmerek 200 mg (5 ml) enkrat na dan prvi dan, potem pa 100 mg (2,5 ml) enkrat na dan še 13 dni.
English: If these medicinal products are co-administered, careful monitoring of full blood counts and adverse events related to increased rifabutin levels (e.g. uveitis) is recommended.
Slovenian: Če pa ta zdravila kljub temu uporabljate sočasno, priporočamo skrbno spremljanje celotne krvne slike in morebitnih neželenih sopojavov, povezanih s povečano koncentracijo rifabutina (npr. uveitisa).
English: Pharmacokinetic / Pharmacodynamic relationships:
Slovenian: Farmakokinetika in farmakodinamični količniki:
English: The other ingredients in the suspension are polysorbate 80, simeticone, sodium benzoate (E211), sodium citrate dihydrate, citric acid monohydrate, glycerol, xanthan gum, liquid glucose, titanium dioxide (E171), artificial cherry flavour containing benzyl alcohol and propylene glycol, and purified water.
Slovenian: Pomožne snovi v suspenziji so polisorbat 80, simetikon, natrijev benzoat (E211), natrijev citrat dihidrat, citronska kislina monohidrat, glicerol, ksantanski gumi, tekoča glukoza, titanov dioksid (E171), umetna aroma češnje, ki vsebuje benzilni alkohol in propilenglikol, in prečiščena voda.
English: Posaconazole is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4 (see section 4.5).
Slovenian: Posakonazol je zaviralec CYP3A4 in ga smete med zdravljenjem z drugimi zdravili, ki se presnovijo s CYP3A4, uporabljati le v posebnih primerih (glejte poglavje 4.5).
English: Rifabutin: Concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk (see section 4.5).
Slovenian: Rifabutin: Izogibajte se sočasni uporabi rifabutina s posakonazolom, razen če korist za bolnika odtehta tveganje (glejte poglavje 4.5).
English: Based on the available data in 16 of these paediatric patients, the safety profile appears to be similar to patients ≥ 18 years of age.
Slovenian: Na podlagi razpoložljivih podatkov za 16 od teh pediatričnih bolnikov so sklepali, da je profil varnosti zdravila podoben kot pri bolnikih, starih ≥ 18 let.
English: Effect of food on oral absorption in healthy volunteers The AUC of posaconazole is about 2.6 times greater when administered with a non-fat meal or nutritional supplement (14 grams fat) and 4 times greater when administered with a high-fat meal (~ 50 grams fat) relative to the fasted state.
Slovenian: Vpliv hrane na peroralno absorpcijo pri zdravih prostovoljcih Vrednost AUC za posakonazol je približno 2,6-krat večja pri uživanju z hrano brez maščob ali s prehranskim dodatkom (14 gramov maščobe) in 4-krat večja pri uživanju z hrano z veliko maščob (~ 50 gramov maščobe) kot pri uživanju zdravila na tešče.
English: The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period.
Slovenian: Primarni končni rezultat učinkovitosti je bila incidenca dokazane oziroma verjetne IFI, kar je ugotavljala neodvisna komisija zunanjih strokovnjakov na slep način, v obdobju na terapiji.
English: Common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000)
Slovenian: Z zdravljenjem povezani neželeni dogodki (TRAE) razporejeni po organskih sistemih in pogostnosti pogosti (≥1/100, <1/10); občasni (≥1/1.000, <1/100); redki (≥1/10.000, <1/1.000) Bolezni krvi in limfatičnega sistema Pogosti: Občasni:
English: Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), efavirenz and cimetidine: Posaconazole concentrations may be significantly lowered in combination; therefore, concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk (see section 4.5).
Slovenian: Rifamicinski antibiotiki (rifampicin, rifabutin), določeni antikonvulzivi (fenitoin, karbamazepin, fenobarbital, primidon), efavirenz in cimetidin: Koncentracija posakonazola je lahko signifikantno znižana pri kombiniranju s temi zdravili, zato se morate izogibati njihovi sočasni uporabi s posakonazolom, razen če korist za bolnika odtehta tveganje (glejte poglavje 4.5).
English: No studies on the effects of posaconazole on the ability to drive and use machines have been performed.
Slovenian: Študij o vplivu posakonazola na sposobnost vožnje in upravljanja s stroji niso izvedli.
English: The effect of other H2 receptor antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. omeprazole) that may suppress gastric acidity for several hours on plasma levels of posaconazole has not been studied but a reduction in bioavailability may occur so that coadministration should be avoided if possible.
Slovenian: Učinka drugih antagonistov receptorjev H2 (npr. famotidin, ranitidin) in zaviralcev protonske črpalke (npr. omeprazol), ki lahko zmanjšajo kislost v želodcu za več ur, na plazemske koncentracije posakonazola še niso proučevali, vendar bi lahko prišlo do zmanjšanja biološke uporabnosti, zato se je potrebno sočasni uporabi izogibati, če je le mogoče.
English: • Any heart rhythm disturbance
Slovenian: • kakršnokoli motnjo srčnega ritma